OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Neuropathic Corneal Pain
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

by Paul | 15th September 2023 | News

London and New York, NY – September 15, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the closing of its previously...

Recent Posts

  • OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
  • OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
  • OKYO Pharma Limited Announces Withdrawal of Public Offering
  • OKYO Pharma Announces Public Offering of Ordinary Shares
  • OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease

Recent Comments

  1. A WordPress Commenter on Hello world!
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023